510(k) Report

FDA product code · Ear, nose and throat

Drug-Eluting Sinus Stent

OWOClass IIIPMA required1 decision since 20111 recall

1 FDA decision since 2011. 1 recall names this code; it is not Class I.

Mechanically maintain patency following ethmoid sinus surgery. By also eluting drugs, reduce the need for post-operative intervention such as surgical adhesion lysis and/or use of oral steroids.

Data to Oct 25, 2026 (FDA decisions) Oct 12, 2026 (recalls) Sep 30, 2026 (MAUDE) refreshed weekly, last Nov 3, 2026 Download the data (CSV)

FIG. A — Illustration, ear, nose and throat panel

Twenty years of OWO at a glance: how often FDA decides these devices, how long 510(k) reviews take, how often they are recalled, and how many adverse event reports name the code.

FDA decisions per year · OWO

3in 2025

2011: 12012: 32013: 82014: 42015: 22016: 52017: 82018: 42019: 82020: 32021: 12022: 32024: 42025: 32026 (partial year): 3
2007high 8 (2013) · low 0 (2007)2026

2026 to Oct 25, outlined.

Median 510(k) review, days · OWO

Too few OWO 510(k)s in any year since 2007 to give a median.

Recalls per year · OWO

1in 2022

2022: 1
2007high 1 (2022) · low 0 (2007)2026

Class I (0 since 2007) Class II/III not classified

Adverse event reports per year · OWO

1in 2025

2012: 12013: 62014: 62015: 62016: 62017: 102018: 42019: 12020: 32021: 12023: 12024: 22025: 1
2007high 10 (2017) · low 0 (2007)2025

MAUDE reports naming product code OWO, not matched to any one device; reports are not rates.

View these four charts as a table
YearDecisionsMedian 510(k) review, daysRecalls (Class I)MAUDE reports
20070—00
20080—00
20090—00
20100—00
20111—00
20123—01
20138—06
20144—06
20152—06
20165—06
20178—010
20184—04
20198—01
20203—03
20211—01
20223—10
20230—01
20244—02
20253—01
20263—0—
FIG. 1 — OWO by year, 2007–2026Sources: FDA decision databases, recall and enforcement reports, MAUDE · Data through Oct 25, 2026

Planning a device in OWO? A 510(k) Report ranks candidate predicates in this code by lineage, citations and recall history, with the review-time outlook.

See the 510(k) Report